{
  "docId": "019de077-19d1-772e-933a-c7f1c42d9b04",
  "docSlug": "d223628377f56d072b5dbf426c21baf1",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 42,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline framework to connect current clinical status to the 'OnTarget 2026' mission.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-19d1-772e-933a-c7f1c42d9b04/41",
  "deckHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04",
  "deckJsonHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04.json",
  "deckAnchorHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.35,
        "x": 0.62,
        "y": 0.15
      },
      "kind": "callout",
      "text": "OnTarget 2026: MISSION: Bringing new, best-in-class medicines to patients with cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c54ba0f-47c4-429b-8255-644658e138af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.08,
        "y": 0.17
      },
      "kind": "framework",
      "text": "2024: EXECUTE ON GLOBAL REGISTRATIONAL STRATEGIES; 2025: FIRST PIVOTAL DATA; 2026: FIRST APPROVED PRODUCT",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50840246-cb60-421b-be82-92a885ce47e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.08,
        "y": 0.43
      },
      "kind": "list",
      "text": "Zidesamtinib (ARROS-1 study for ROS1+ NSCLC): Phase 2 ongoing with registrational intent; NVL-655 (ALKOVE-1 study for ALK+ NSCLC): Phase 2 ongoing; NVL-330 for HER2+ NSCLC: Planned Phase 1 initiation in 2024; Additional Discovery Research Programs Ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3d91d25-43dc-4b7e-ad0d-d88fd24dc24a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.37,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "The Path to Patient Impact",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4584e102-4638-413d-be02-5f5144eb2afa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "df9e6c4b-757f-4208-ad6f-9ae711f541e7",
      "evidence": "Chronological progression of goals from 2024 to 2026.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}